COCP - Cocrystal's soars 11% as CDI-45205 shows excellent antiviral activity against SARS-CoV-2 and variants

Cocrystal Pharma (COCP) jumps 11.2% premarket after announcing that its protease inhibitor CDI-45205 is active against SARS-CoV-2 and two variants.Two reference inhibitors including remdesivir and PF-00835231 were included in the study as comparators.Results showed CDI-45205 had excellent antiviral activity against the U.K. variant, with an EC50 of 1.9 uM (remdesivir EC50 0.6 uM; PF-00835231 EC50 >100 uM) and against the South African variant, with an EC50 of 2.5 uM (remdesivir EC50 0.8 uM; PF-00835231 EC50 >100 uM) in the absence of a P-glycoprotein efflux inhibitor. In mouse and rat pharmacokinetic studies, CDI-45205 showed good bioavailability, and also no cytotoxicity against a variety of human cell lines.Additionally, a proof-of-concept animal study demonstrated that daily injection of CDI-45205 exhibited favorable in vivo efficacy in MERS-CoV-infected mice.

For further details see:

Cocrystal’s soars 11% as CDI-45205 shows excellent antiviral activity against SARS-CoV-2 and variants